Logo image of AFME.PA

AFFLUENT MEDICAL SA (AFME.PA) Stock Fundamental Analysis

EPA:AFME - Euronext Paris - Matif - FR0013333077 - Common Stock - Currency: EUR

1.43  +0.01 (+1.06%)

Fundamental Rating

0

AFME gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 58 industry peers in the Health Care Equipment & Supplies industry. AFME may be in some trouble as it scores bad on both profitability and health. AFME is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AFME has reported negative net income.
AFME had a negative operating cash flow in the past year.
In the past 5 years AFME always reported negative net income.
AFME had a negative operating cash flow in each of the past 5 years.
AFME.PA Yearly Net Income VS EBIT VS OCF VS FCFAFME.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

AFME has a Return On Assets of -27.82%. This is in the lower half of the industry: AFME underperforms 74.14% of its industry peers.
AFME has a Return On Equity of -60.06%. This is in the lower half of the industry: AFME underperforms 75.86% of its industry peers.
Industry RankSector Rank
ROA -27.82%
ROE -60.06%
ROIC N/A
ROA(3y)-24.72%
ROA(5y)-24.33%
ROE(3y)-42.9%
ROE(5y)-44.57%
ROIC(3y)N/A
ROIC(5y)N/A
AFME.PA Yearly ROA, ROE, ROICAFME.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2019 2020 2021 2022 2023 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AFME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AFME.PA Yearly Profit, Operating, Gross MarginsAFME.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2019 2020 2021 2022 2023 -5K -10K -15K -20K

More info and screens

0

2. Health

2.1 Basic Checks

AFME has more shares outstanding than it did 1 year ago.
AFME has a worse debt/assets ratio than last year.
AFME.PA Yearly Shares OutstandingAFME.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2019 2020 2021 2022 2023 10M 20M 30M
AFME.PA Yearly Total Debt VS Total AssetsAFME.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

AFME has an Altman-Z score of -1.27. This is a bad value and indicates that AFME is not financially healthy and even has some risk of bankruptcy.
AFME's Altman-Z score of -1.27 is on the low side compared to the rest of the industry. AFME is outperformed by 74.14% of its industry peers.
AFME has a Debt/Equity ratio of 0.55. This is a neutral value indicating AFME is somewhat dependend on debt financing.
The Debt to Equity ratio of AFME (0.55) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF N/A
Altman-Z -1.27
ROIC/WACCN/A
WACCN/A
AFME.PA Yearly LT Debt VS Equity VS FCFAFME.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2019 2020 2021 2022 2023 0 20M 40M 60M

2.3 Liquidity

AFME has a Current Ratio of 0.45. This is a bad value and indicates that AFME is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.45, AFME is not doing good in the industry: 87.93% of the companies in the same industry are doing better.
AFME has a Quick Ratio of 0.45. This is a bad value and indicates that AFME is not financially healthy enough and could expect problems in meeting its short term obligations.
AFME has a worse Quick ratio (0.45) than 82.76% of its industry peers.
Industry RankSector Rank
Current Ratio 0.45
Quick Ratio 0.45
AFME.PA Yearly Current Assets VS Current LiabilitesAFME.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2019 2020 2021 2022 2023 5M 10M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.25% over the past year.
EPS 1Y (TTM)33.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -7.04% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y19.61%
EPS Next 2Y-16.82%
EPS Next 3Y-7.04%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AFME.PA Yearly Revenue VS EstimatesAFME.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2026 1M 2M 3M
AFME.PA Yearly EPS VS EstimatesAFME.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AFME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AFME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AFME.PA Price Earnings VS Forward Price EarningsAFME.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AFME.PA Per share dataAFME.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as AFME's earnings are expected to decrease with -7.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.82%
EPS Next 3Y-7.04%

More info and screens

0

5. Dividend

5.1 Amount

AFME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AFFLUENT MEDICAL SA

EPA:AFME (5/28/2025, 7:00:00 PM)

1.43

+0.01 (+1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners9.52%
Ins Owner ChangeN/A
Market Cap56.27M
Analysts86.67
Price Target4.11 (187.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.83%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.16
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0
BVpS0.66
TBVpS-0.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.82%
ROE -60.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.72%
ROA(5y)-24.33%
ROE(3y)-42.9%
ROE(5y)-44.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.83%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.45
Quick Ratio 0.45
Altman-Z -1.27
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)9.3%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.42%
EPS Next Y19.61%
EPS Next 2Y-16.82%
EPS Next 3Y-7.04%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.21%
EBIT Next 3Y-3.01%
EBIT Next 5YN/A
FCF growth 1Y45.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.83%
OCF growth 3YN/A
OCF growth 5YN/A